Posted by Michael Wonder on 15 Oct 2020
Health Canada approves first-ever gene replacement therapy, Luxturna
15 October 2020 - Luxturna (voretigene neparvovec), is the first approved therapy for previously untreatable inherited retinal disease.
Novartis Pharmaceuticals Canada is pleased to announce that Health Canada has approved Luxturna (voretigene neparvovec), a one-time gene therapy for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
The presence of biallelic RPE65 mutations should be confirmed by an accredited laboratory using validated assay methods.
